옵션 체인은 다양한 행사가격과 만기일에 대한 Genmab의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Genmab에 대한 시장 심리를 평가합니다..

Genmab (NASDAQ:GMAB) 주식, 옵션 체인

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) is scheduled to report its fiscal second quarter earnings on Thursday.
The company is likely to report its revenues, gross margins and earnings in-line with consensus expectations, although guidance is expected to be soft, according to JPMorgan.
The Micron Technology Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59f1c1bdefacff0001706787/harlan-sur">Analyst Harlan Sur</a> maintained an Overweight rating and price target of $145.
The Micron Technology Thesis: Supported by sustained momentum in HBM demand trends, DRAM pricing trends have been strong, offsetting "softer NAND bit shipments and ASPs resulting from elevated inventory across consumer facing end markets (PC/smartphone)," Sur said in a note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Micron Technology is likely to provide soft guidance for the fiscal third quarter, with revenue, gross margin, and earnings short of consensus expectations, he added.
The company continues to have a strong share of key Nvidia Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) platforms, the analyst stated.
"Consistent with what MU laid out at a recent investor conference, we expect May-Qtr revenue to grow Q/Q on strong bit shipments with gross margin trending lower by a few 100 basis points Q/Q and below consensus expectations," he further wrote.
MU Price Action: Shares of Micron Technology had declined by 2.11% to $100.93 at the time of publication on Tuesday.
Read More: <a href="https://www.benzinga.com/insights/analyst-ratings/25/02/43568843/forecasting-the-future-6-analyst-projections-for-tradeweb-markets">&nbsp;Semtech Posts Better-Than-Expected Earnings, Joins Rubrik, DocuSign, PagerDuty And Other Big Stocks Moving Higher On Friday</a>
Image via Shutterstock

Analyst Color

Reiteration

Analyst Ratings

NVDA

Micron Technology Q2 Earnings Preview: Results In-Line, Soft Guide Likely

Truist Securities analyst Neal Dingmann maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Buy and raises the price target from $220 to $235.

Price Target

TRGP

Truist Securities Maintains Buy on Targa Resources, Raises Price Target to $235

Loop Capital analyst Rob Sanderson maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Buy and lowers the price target from $23 to $20.

LYFT

Loop Capital Maintains Buy on Lyft, Lowers Price Target to $20

Advanced Micro Devices's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NYSE">AMD</a>) short percent of float has risen 7.65% since its last report. The company recently reported that it has 56.78 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Advanced Micro Devices Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742307327_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Advanced Micro Devices has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Advanced Micro Devices's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Advanced Micro Devices's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around Advanced Micro Devices?

Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) has outperformed the market over the past 5 years by 25.57% on an annualized basis producing an average annual return of 45.81%. Currently, Orla Mining has a market capitalization of $2.97 billion. 
Buying $1000 In ORLA: If an investor had bought $1000 of ORLA stock 5 years ago, it would be worth $7,955.60 today based on a price of $9.23 for ORLA at the time of writing.
<h3>Orla Mining's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742307323_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORLA

Here's How Much $1000 Invested In Orla Mining 5 Years Ago Would Be Worth Today

Carvana's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) short percent of float has fallen 11.71% since its last report. The company recently reported that it has 9.26 million shares sold short, which is 8.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Carvana Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742307323_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carvana has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carvana's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Carvana's peer group average for short interest as a percentage of float is 10.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CVNA

Is Carvana Gaining or Losing Market Support?

Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) shares are trading relatively flat on Tuesday.
Today, the company said it is entering into a strategic partnership with Shield AI to deliver AI-powered autonomous solutions <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44372895/booz-allen-and-shield-ai-partnership-brings-new-autonomous-airborne-solutions-to-u-s-military" rel="noreferrer noopener">for the U.S. government.</a>
This collaboration aims to combine Booz Allen&#8217;s mission engineering expertise with Shield AI&#8217;s Hivemind Enterprise platform, initially focusing on enhancing the Department of Defense&#8217;s capabilities.
Booz Allen recently made its largest corporate venture capital investment to date in Shield AI&#8217;s strategic funding round. This investment aims to expand the deployment of Hivemind and enhance the development of autonomy products crucial for national security.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, BAH stock has lost over 20% in the past year. Investors can gain exposure to the stock via ETF Series Solutions U.S. Global Technology and Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAR#NYSE">WAR</a>).
Also Read: <a target="_blank" href="http://benzinga.com/25/03/44376164/clean-tech-company-n2off-signs-deal-for-380-mw-energy-storage-projects-in-italy" rel="noreferrer noopener">Clean Tech Company N2OFF Signs Deal For 380 MW Energy Storage Projects In Italy</a>
The latest partnership is poised to accelerate the development and integration of AI-driven control systems and autonomy into uncrewed systems, which will play a pivotal role in providing the U.S. military with a crucial advantage in complex operational scenarios.
The collaboration&#8217;s goal is to equip the U.S. armed forces with autonomous technologies to protect troops and improve decision-making under threat.
Shield AI&#8217;s Hivemind software powers autonomous vehicles, ranging from drones to fighter jets like the F-16, even in GPS-denied or jamming situations.
The partnership also holds significant potential for other national security missions, positioning both companies to bring advanced AI capabilities to critical defense initiatives.
Steve Escaravage, president of Booz Allen&#8217;s Defense Technology Group, emphasized the evolving nature of adversarial threats and the importance of this partnership in maintaining U.S. military superiority.
Earlier this month, Booz Allen announced that its wholly-owned subsidiary, Booz Allen Hamilton has priced a $650 million aggregate principal amount of its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44266151/booz-allen-hamilton-announces-pricing-of-senior-notes-offering" rel="noreferrer noopener">5.950% Senior Notes due 2035.</a>
Price Action: BAH shares are trading lower by 0.48% to $114.79 at last check Tuesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/03/44374034/volkswagens-audi-to-slash-7500-jobs-by-2029-to-boost-competitiveness" target="_blank" rel="noreferrer noopener">Volkswagen&#8217;s Audi To Slash Up To 7,500 Jobs By 2029 To Boost Competitiveness</a></li>
</ul>
Image via Shutterstock.

Markets

General

Booz Allen Joins Forces With Shield AI To Supercharge US Military Autonomy: Details

Silgan Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLGN#NYSE">SLGN</a>) short percent of float has fallen 4.0% since its last report. The company recently reported that it has 2.89 million shares sold short, which is 3.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Silgan Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742307317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Silgan Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Silgan Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Silgan Hldgs's peer group average for short interest as a percentage of float is 4.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SLGN

What's Driving the Market Sentiment Around Silgan Hldgs?

Loop Capital analyst Anthony Chukumba maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Hold and lowers the price target from $120 to $75.

FIVE

Loop Capital Maintains Hold on Five Below, Lowers Price Target to $75

Truist Securities analyst Tobey Sommer maintains Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) with a Hold and lowers the price target from $135 to $115.

SAIC

Truist Securities Maintains Hold on Science Applications Intl, Lowers Price Target to $115

WIIM

GOOG

GOOGL

Alphabet shares are trading lower after the company announced it will acquire Wiz for $32 billion.

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.56% to 41,608.14 while the NASDAQ dipped 1.49% to 17,542.81. The S&amp;P 500 also fell, dropping, 0.92% to 5,622.68.
Check This Out: <a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a>
Leading and Lagging Sectors Energy shares jumped by 0.5% on Tuesday.
In trading on Tuesday, consumer discretionary shares fell by 2%.
Top Headline
U.S. industrial production increased by 0.7% in February, surpassing market estimates of 0.2%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares shot up 57% to $6.88 after the company announced it submitted an application for four new federal funding opportunities.</li>
<li>Shares of Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>)got a boost, surging 57% to $0.1351. Syros Pharmaceuticals recently announced a voluntary delisting from the Nasdaq and SEC deregistration.</li>
<li>Heidmar Maritime Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMR#NASDAQ">HMR</a>) shares were also up, gaining 38% to $3.75.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares dropped 46% to $0.4785.</li>
<li>Shares of AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) were down 44% to $0.9017. AirNet Technology recently announced the execution of a non-binding investment LOI with LLP STH Corp, a Kazakstan company.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) was down, falling 37% to $0.0669.</li>
</ul>
Commodities In commodity news, oil traded up 0.5% to $67.94 while gold traded up 1.2% at $3,041.60.
Silver traded up 1.6% to $34.840 on Tuesday, while copper rose 0.7% to $4.9920.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.46%, Germany's DAX 40 jumped 0.63% and France's CAC 40 gained 0.43%. Spain's IBEX 35 Index rose 1.10%, while London's FTSE 100 rose 0.32%.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei gaining 1.20%, China's Shanghai Composite Index gaining 0.11%, Hong Kong's Hang Seng Index surging 2.46% and India's BSE Sensex gaining 1.53%.
Economics
<ul>
<li>U.S. housing starts surged 11.2% month-over-month to an annualized rate of 1.501 million in February following a revised 1.35 million in January.</li>
<li>Building permits declined by 1.2% to an annualized rate of 1.456 million in February.</li>
<li>U.S. import prices increased by 0.4% in February, versus market estimates of a 0.1% decline.</li>
<li>U.S. export prices rose by 0.1% month-over-month in February.</li>
<li>U.S. industrial production increased by 0.7% in February, surpassing market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44325485/wall-streets-most-accurate-analysts-spotlight-on-3-real-estate-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Eurozone

Commodities

ADTX

AGMH

ANTE

ATXI

SYRS

Dow Dips Over 200 Points; US Industrial Production Increases More than Expected

Guggenheim analyst Vamil Divan reiterates Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) from Buy to Buy.

Guggenheim Reiterates Buy on Pfizerto Buy

Truist Securities analyst Michael Lewis maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Hold and raises the price target from $17 to $18.

SBRA

Truist Securities Maintains Hold on Sabra Health Care REIT, Raises Price Target to $18

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $109 price target.

MRUS

Guggenheim Reiterates Buy on Merus, Maintains $109 Price Target

Truist Securities analyst Michael Lewis maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Hold and raises the price target from $38 to $39.

Truist Securities Maintains Hold on Omega Healthcare Invts, Raises Price Target to $39

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Hold and lowers the price target from $74 to $72.

INCY

Truist Securities Maintains Hold on Incyte, Lowers Price Target to $72

Guggenheim analyst Joseph Osha reiterates Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) with a Buy and maintains $7 price target.

EOSE

Guggenheim Reiterates Buy on Eos Energy Enterprises, Maintains $7 Price Target

Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Hold and lowers the price target from $90 to $82.

GMED

Truist Securities Maintains Hold on Globus Medical, Lowers Price Target to $82

XPEV

XPeng shares are trading lower after the company reported a Q4 Adj EPS miss.

Press Releases

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Comments

Genmab

Genmab (GMAB) 옵션

Genmab (NASDAQ:GMAB) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌